"Odd,,,very odd,,,,,,!! Where do we differ? Is it really just the exchange we trade on?"
No. The market has punished RVX due to its top-line failures of two consecutive clinical trials but it's willing to give it the benefit of the doubt in a BOM2. The share price could have easily fallen below the 50 cent mark by now, but it held on.
"It ain't over till the fat lady sings." Hang in there, folks.
Koo